• NEWS DESK

DRUG DEVELOPERS TAKE FRESH AIM


FRANKFURT/ZURICH (Reuters) - Dozens of drugmakers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows.

These antibody-drug conjugates, or ADCs, from companies including AztraZeneca and GlaxoSmithKline, are described by researchers as “guided missiles” packing a powerful anti-cancer punch.

Read More


amazon smile for pragnya.png
Our Non- Profit Partners
pragnya_logo.png
LOCAL EVENTS
BAY AREA NEWS

Powered by Studio M | 1917 Concourse Dr. San Jose CA 95131